A carregar...
HER3 targeting with an antibody‐drug conjugate bypasses resistance to anti‐HER2 therapies
Despite impressive clinical benefit obtained with anti‐HER2‐targeted therapies, in advances stages, especially in the metastatic setting, HER2‐positive tumors remain incurable. Therefore, it is important to develop novel strategies to fight these tumors, especially when they become resistant to avai...
Na minha lista:
| Publicado no: | EMBO Mol Med |
|---|---|
| Main Authors: | , , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
John Wiley and Sons Inc.
2020
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7207167/ https://ncbi.nlm.nih.gov/pubmed/32329582 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.15252/emmm.201911498 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|